About Psoriasis

 

Psoriasis is a chronic, relapsing-remitting disease driven by dysregulated interactions between the innate and adaptive immune systems and the keratinocyte compartment of the skin. It manifests in several clinically distinct forms, the most common of which is plaque psoriasis (psoriasis vulgaris), accounting for approximately 80–90% of cases. Other recognized variants include guttate psoriasis, characterized by small, drop-shaped lesions often following streptococcal infection; inverse psoriasis, presenting in intertriginous areas with smooth, erythematous plaques lacking prominent scale; pustular psoriasis, marked by sterile pustules either localized or generalized; and erythrodermic psoriasis, a rare but potentially life-threatening form involving widespread erythema and desquamation.

Clinically, plaque psoriasis typically presents on the scalp, extensor surfaces of the elbows and knees, lower back, and umbilical region, though any cutaneous site may be affected. Nail involvement — including pitting, onycholysis, and subungual hyperkeratosis — occurs in up to 50% of patients and may signal increased risk of psoriatic arthritis. Disease severity is classified along a clinical spectrum based on body surface area involvement, lesion characteristics, anatomical location, and impact on quality of life, with validated tools such as the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) guiding clinical assessment.

​

Causes

 

The pathogenesis of psoriasis is multifactorial, governed by an interplay of genetic, immunologic, and environmental mechanisms operating along a complex inflammatory axis:

The first is immune dysregulation, specifically driven by activation of the IL-23/Th17 axis. Dendritic cell activation leads to release of IL-23, which promotes differentiation and maintenance of Th17 lymphocytes; these in turn secrete IL-17A, IL-17F, IL-22, and TNF-α, driving keratinocyte hyperproliferation, neutrophil recruitment, and amplification of the inflammatory cascade. The second is keratinocyte hyperproliferation, in which the normal 28-day epidermal turnover cycle is accelerated to 3–5 days, producing the characteristic thickened plaques and silvery scale as immature keratinocytes accumulate at the skin surface. The third is genetic predisposition, with strong heritability evidenced by familial clustering and identification of susceptibility loci, most notably HLA-Cw6 within the PSORS1 region, alongside polymorphisms in genes regulating innate immunity, antigen presentation, and skin barrier function.

Secondary contributing factors and recognized triggers include streptococcal and other infections, mechanical trauma to the skin (the Koebner phenomenon), psychological stress, smoking, excessive alcohol consumption, obesity, certain medications (beta-blockers, lithium, antimalarials, systemic corticosteroid withdrawal, and select biologics), hormonal fluctuations, and climatic factors such as cold, dry conditions and reduced sun exposure.

​

Treatment

 

Effective psoriasis management is stepwise and individualized to disease severity, anatomical distribution, comorbidities, patient preference, and quality-of-life impact. Therapy spans topical, phototherapy, conventional systemic, and biologic categories, with treatment intensity escalated according to clinical response.

Topical therapies form the cornerstone of treatment for mild to moderate disease and serve as adjuncts in more severe presentations. Topical corticosteroids, selected by potency to match lesion severity and anatomical site, remain the most widely prescribed first-line agents. Vitamin D analogues (calcipotriol, calcitriol) normalize keratinocyte proliferation and differentiation, and are frequently combined with topical corticosteroids for synergistic effect. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) offer a steroid-sparing option particularly suited to facial and intertriginous involvement. Keratolytics such as salicylic acid, coal tar preparations, and dithranol (anthralin) provide additional options for plaque reduction, while newer agents including tapinarof (an aryl hydrocarbon receptor agonist) and roflumilast (a topical PDE-4 inhibitor) expand the non-steroidal therapeutic armamentarium.

Phototherapy is indicated for moderate to extensive disease unresponsive to topicals. Narrowband UVB (311–313 nm) is the most widely used modality, offering favorable efficacy and safety. Psoralen plus UVA (PUVA) remains an option for selected refractory cases, with appropriate consideration of long-term cutaneous risks. Targeted excimer laser therapy is useful for localized, treatment-resistant plaques.

Conventional systemic therapies are indicated for moderate to severe disease, treatment-resistant cases, or significant quality-of-life impact. Methotrexate, ciclosporin, and acitretin have long-established roles, each with distinct mechanism, efficacy profile, and monitoring requirements. Apremilast, an oral PDE-4 inhibitor, offers a favorable safety profile and is suitable for patients who are not candidates for traditional systemic agents. Deucravacitinib, an oral selective TYK2 inhibitor, represents a newer addition to the systemic landscape.

Biologic therapies have transformed the treatment of moderate to severe psoriasis through selective targeting of key inflammatory mediators. TNF-α inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol) were the first biologics approved and remain widely used. IL-12/23 inhibition is achieved with ustekinumab. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) offer rapid and substantial skin clearance through targeted blockade of the Th17 axis. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provide selective upstream targeting with extended dosing intervals and high rates of sustained clearance. All biologic therapy requires appropriate screening for infection, tuberculosis, and other relevant comorbidities prior to initiation.

Adjunctive interventions include emollients to support barrier function and reduce scaling, psychological support given the well-documented impact on mental health, and coordinated management of associated comorbidities such as psoriatic arthritis, cardiovascular risk factors, and metabolic disease.

​

Solution

 

A durable solution to psoriasis is rarely a single intervention but rather a sustained, individualized regimen anchored in three principles: inflammation control, skin barrier support, and comprehensive health management.

Inflammation control involves the appropriate, escalated use of evidence-based therapies matched to disease severity, with timely treatment intensification when clinical response is inadequate. Skin barrier support begins with daily skincare habits — gentle, fragrance-free cleansing, lukewarm rather than hot bathing, and consistent application of emollients to reduce scaling, soothe pruritus, and improve the penetration of active topical agents. Comprehensive health management addresses the systemic dimension of psoriasis, including regular cardiovascular risk assessment, screening for psoriatic arthritis, attention to metabolic health, and proactive support for mental wellbeing.

Equally important are lifestyle considerations: maintaining a healthy body weight, limiting alcohol intake, smoking cessation, managing stress through behavioral and mindfulness-based interventions, ensuring adequate sleep, and supporting overall health through balanced nutrition rich in anti-inflammatory foods. Patients should be counseled that psoriasis is a chronic condition that may wax and wane over years or decades, that adherence to a long-term treatment plan is the strongest predictor of sustained control, and that modern therapeutic options can achieve clear or nearly clear skin in the majority of patients.

With a structured, evidence-based approach and ongoing collaboration between patient and clinician, psoriasis is a highly manageable condition, and meaningful, sustained improvement in skin appearance, physical comfort, and overall quality of life is an achievable outcome for the vast majority of patients.

 

Products